Tenof EMT (Tenofovir + Emtricitabine) – Reliable HIV Treatment & Prevention | GlobMedIndia
Tenof EMT is a combination antiviral medicine containing Tenofovir Disoproxil Fumarate and Emtricitabine. It is widely used in antiretroviral therapy (ART) for HIV-1 infection and also prescribed for HIV prevention in high-risk individuals. This dual-action formulation helps suppress viral replication and supports immune system health.
📞 Phone/WhatsApp: +91 9730316395
🌐 Website: https://globmedindia.com
Uses:
✔ Treatment of HIV-1 infection (as part of combination therapy)
✔ Pre-Exposure Prophylaxis (PrEP) for HIV prevention
✔ Post-Exposure Prophylaxis (PEP) when prescribed
✔ Helps reduce viral load and improve immune response
Dosage:
💊 One tablet once daily or as prescribed by physician
💊 Can be taken with or without food
💊 Take at the same time each day for best results
💊 Dose adjustment may be required in renal impairment
Treatment:
✔ First-line antiretroviral therapy component
✔ Used in combination with Dolutegravir, Efavirenz, or other ART drugs
✔ Long-term HIV management and prevention strategy
✔ Helps maintain viral suppression
Advantages:
⭐ Dual antiviral combination for effective control
⭐ Once-daily convenient dosing
⭐ WHO-recommended regimen
⭐ Well tolerated in long-term use
⭐ Reduces HIV transmission risk
Storage Conditions:
📦 Store below 30°C
📦 Keep in a cool and dry place
📦 Protect from moisture and direct sunlight
📦 Keep out of reach of children
Alternative Indian Brands:
• Tenvir-EM – Cipla
• Ricovir-EM – Mylan/Viatris
• Tavin-EM – Emcure
• Tenof-EM – Hetero
• Viropil – Cipla
• Truvada – Gilead (available in India)
• Taficita EM – Emcure
GlobMedIndia – The Medicine Exporter
Get fast & safe delivery for anti-cancer and specialty medicines to India and worldwide:
🌍 South Korea | Africa | Thailand | Vietnam | Middle East | South East Countries
#TenofEMT #TenofovirEmtricitabine #HIVTreatment #PrEP #AntiviralMedicine #GlobMedIndia #MedicineExporter #PharmaExporter #SouthKorea #Africa #Thailand #Vietnam #MiddleEast #SoutheastAsia #OncologyMedicines #GlobalPharma